Alliance Foundation Trials And Natera Launch AFT-70 NAVIGATE, Randomized Phase III Trial Evaluating MRD-Guided Treatment Strategy For Patients With Intermediate And High-Risk ER-Positive/HER2-Negative Early Breast Cancer
Trial will use Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s investigational oral SERD, aiming to spare patients unnecessary
Natera is running a big cancer study with a partner company. The test helps doctors figure out which patients need extra treatment.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.